Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine in hospitalized adults with human metapneumovirus infection
2017-001696-22Phase 2Suspended
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human metapneumovirus infection (HMPV) comparing Lumicitabine regimen(s) with Placebo (2 arms). Primary endpoint: hMPV viral load AUC from baseline to Day 7. Started May 2018; status: suspended.
02
Drugs
lumicitabine
03
Conditions
human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on 2017-001696-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001696-22.